Cancer cell cycle control

Anticancer Research

Volumn 19, Issue 6 A, 1999, Pages 4772-4780

  Funk, Jens Oliver ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

CDK; Cell cycle; Cyclin; p21(CIP1); Tumor suppressor

Indexed keywords

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CELL CYCLE PARAMETERS; CELL PROLIFERATION; DNA REPAIR; DNA SYNTHESIS; GENETIC STABILITY; HUMAN; MITOSIS INHIBITION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

CELL CYCLE; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS;

EID: 0033380474     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Lengauer C, Kinzler KW and Vogelstein B: Genetic instabilities in human cancers. Nature 396: 643-649, 1998.
2. Hartwell LH and Kastan MB: Cell cycle control and cancer. Science 266: 1821-1828, 1994.
3. Murray AW: Creative blocks: cell-cycle checkpoints and feedback controls. Nature 359: 599-604, 1992.
4. Morgan DO: Principles of CDK regulation. Nature 374: 131-134, 1995.
5. Sherr CJ and Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149-1163, 1995.
6. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
7. Hartwell LH and Weinert TA: Checkpoints: controls that ensure the order of cell cycle events. Science 246: 629-634, 1989.
8. Paulovich AG, Toczyski DP and Hartwell LH: When checkpoints fail. Cell 88: 315-321, 1997.
9. Weinberg RA: The retinoblasoma protein and cell cycle control. Cell 81: 323-330, 1995.
10. Beijersbergen RL and Bernards R: Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochim Biophys Acta 103-120, 1996.
11. Adams PD and Kaelin WG: The cellular effects of E2F over-expression. Curr Topics Microbiol Immunol 208: 79-93, 1996.
12. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM and Pagano M: Human cyclin E, a nuclear protein essential for the G1 to S phase transition. Mol Cell Biol 15: 2612-2624, 1995.
13. Lukas J, Herzinger T, Hansen K, Moroni MC, Resnitzky D, Helin K, Reed SI and Bartek J: Cyclin E-induced S phase without activation of the pRB/E2F pathway. Genes Dev 11: 1479-1492, 1997.
14. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
15. Schwartz D and Rotter V: p53-dependent cell cycle control: response to genotoxic stress. Sem Cancer Biol 8: 325-336, 1998.
16. Giaccia AJ and Kastan MB: The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12: 2973-2983, 1998.
17. Waldman T, Kinzler KW and Vogelstein B: p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55: 5187-5190, 1995.
18. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T and Hannon GJ: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377: 552-557, 1995.
19. Lane DP and Hall PA: MDM2 - arbiter of p53's destruction. Trends Biochem Sci 22: 372-374, 1997.
20. Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee H-W, Cordon-Cardo C and DePhino RA: The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723, 1998.
21. Zhang Y, Xiong Y and Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734, 1998.
22. Alevizopoulos K, Vlach J, Hennecke S and Amati B: Cyclin E and C-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. EMBO J 16: 5322-5333, 1997.
23. Lammie GA, Fantl V, Smith R, Schuuring E, Brookes S, Michalides R, Dickson C, Arnold A and Peters G: D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 6: 439-444, 1991.
24. Hunter T and Pines J: Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994.
25. Hirama T and Koeffler HP: Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86: 841-854, 1995.
26. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ and Pardee AB: Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54: 380-385, 1994.
27. Wang J, Zindy F, Chenivesse X, Lamas E, Henglein B and Brechot C: Modification of cyclin A expression by hepatitis B virus DNA integration in a hepatocellular carcinoma. Oncogene 7: 1653-1656, 1992.
28. Wölfel T, Hauer M, Schneider J, Serrano M, Wölfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Büschenfelde K-H and Beach D: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281-1284, 1995.
29. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N and Dracopoli NC: Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12: 97-99, 1996.
30. Zhu L, Harlow E and Dynlacht BD: p107 uses a p21C1P1-related domain to bind cyclin/cdk2 and regulate interactions with E2F. Genes Dev 9: 1740-1752, 1995.
31. Chen J, Saha P, Kornbluth S, Dynlacht BD and Dutta A: Cyclinbinding motifs are essential for the function of p21CIP1. Mol Cell Biol 16: 4673-4682, 1996.
32. Adams PD, Sellers WR, Sharma SK, Wu AD, Nalin CM and Kaelin WG: Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol Cell Biol 16: 6623-6633, 1996.
33. Funk JO and Galloway DA: Inhibiting CDK inhibitors: new lessons from DNA tumor viruses. Trends Biochem Sci 23: 337-341, 1998.
34. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A and Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev 11: 847-862, 1997.
35. Li X-S, Rishi AK, Shao Z-M, Dawson MI, Jong L, Shroot B, Reichert U, Ordonez J and Fontana JA: Posttranscriptional regulation of p21WAF1/CIP1 expression in human breast carcinoma cells. Cancer Res 56: 5055-5062, 1996.
36. Timchenko NA, Harris TE, Wilde M, Bilyeu TA, Burgess-Beusse BL, Finegold MJ and Darlington GJ: CCAAT/enhancer binding protein a regulates p21 protein and hepatocyte proliferation in newborn mice. Mol Cell Biol 17: 7353-7361, 1997.
37. Maki CG and Howley PM: Ubiquitinalion of p53 and p21 is differentially affected by ionizing and UV irradiation. Mol Cell Biol 17: 355-363, 1997.
38. Waga S, Hannon GJ, Beach D and Stillman B: The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578, 1994.
39. Li R, Waga S, Hannon GJ, Beach D and Stillman B: Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371: 534-537, 1994.
40. Ball KL, Lain S, Fåhraeus R, Smythe C and Lane DP: Cell-cycle arrest and inhibition of cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr Biol 7: 71-80, 1996.
41. Ogryzko VV, Wong P and Howard BH: WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol 17: 4877-4882, 1997.
42. Elledge SJ, Winston J and Harper JW: A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis. Trends Cell Biol 6: 388-392, 1996.
43. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR and Roberts JM: Expression of the cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222-225, 1997.
44. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K and Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85: 733-744, 1996.
45. Fero ML, Randel E, Gurley KE, Roberts JM and Kemp CJ: The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396: 177-180, 1998.
46. Knudson AGJ: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68: 820-823, 1971.
47. Quelle DE, Zindy F, Ashmun RA and Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000, 1995.
48. Chin L, Pomerantz J and DePinho RA: The INK4a/ARF tumor suppressor: one gene - two products - two pathways. Trends Biochem Sci 23: 291-296, 1998.
49. Kamb A: Cell-cycle regulators and cancer. Trends Gen 11: 136-140, 1995.
50. Chin L, Merlino G and DePinho RA: Maligant melanoma: modern black plague and genetic black box. Genes Dev 12: 3467-3481, 1998.
51. Serrano M, Lee H-W, Chin L, Cordon-Cardo C, Beach D and DePinho RA: Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27-37, 1996.
52. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, Horner III JW and DePinho RA: Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 11: 2822-2834, 1997.
53. Sherr CJ: Tumor surveillance via the ARF-p53 pathway. Genes Dev 12: 2984-2991, 1998.
54. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G and Sherr CJ: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame producer p19ARF. Cell 91: 649-659, 1947.
55. Stott F, Bates SA, James M, McConnell BB, Starborg M, Brookes S, Palmero I, Hara E, Vousden KH and Peters G: The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17: 5001-5014, 1998.
56. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ and Roussel MF: Myc signaling via the ARF tumor suppressor regulated p53-dependent apoptosis and immortalization. Genes Dev 12: 2424-2433, 1998.
57. de Stanchina E, McCurrach ME, Zindy F, Shich S-Y, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ and Lowe SW: E1A signaling to p53 involves the p19ARF tumor suppressor. Genes Dev 12: 2435-2443, 1998.
58. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ and Kouzarides T: Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 91: 597-601, 1998.
59. Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D and Harel-Bellan A: Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391: 601-605, 1998.
60. Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR and Howley PM: Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA 93: 4350-4354, 1996.
61. DeGregori J, Kowalik T and Nevins JR: Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/s-regulatory genes. Mol Cell Biol 15: 4215-4224, 1995.
62. Zerfass K, Schulze A, Spitkovsky D, Friedman V, Henglein B and Jansen-Dürr P: Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation. J Virol 69: 6389-6399, 1995.
63. Martin LG, Demers GW and Galloway DA: Disruption of the G1/S transition in human papillomavirus type 16 E7-expressing human cells is associated with altered regulation of cyclin E. J Virol 72: 975-985, 1998.
64. Jones DL and Münger K: Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. J Virol 71: 2905-2912, 1997.
65. Demers GW, Espling E, Harry JB, Etscheid BG and Galloway DA: Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J Virol 70: 6862-6869, 1996.
66. Dimri GP, Nakanishi M, Desprez P-Y, Smith JR and Campisi J: Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol Cell Biol 16: 2987-2997, 1996.
67. Hiyama H, Iavarone A and Reeves SA: Regulation of the cdk inhibitor p21 gene during cell cycle progression is under the control of the transcription factor E2F. Oncogene 16: 1513-1523, 1998.
68. Mal A, Poon RYC, Howe PH, Toyoshima H, Hunter T and Harter ML: Inactivation of p27Kip1 by the viral E1A oncoprotein in TGFb-treated cells. Nature 380: 262-265, 1996.
69. Zerfass-Thome K, Zwerschke W, Mannhardt B, Tindle R, Botz JW and Jansen-Dürr P: Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 13: 2323-2330, 1996.
70. Funk JO, Waga S, Harry JB, Espling E, Stillman B and Galloway DA: Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 11: 2090-2100, 1997.
71. Jones DL, Alani RM and Münger K: The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip-mediated inhibition of cdk2. Genes Dev 11: 2101-2111, 1997.
72. Hofmann F and Livingston DM: Differential effects of cdk2 and cdk3 on the control of pRb and E2F function during G1 exit. Genes Dev 10: 851-861, 1996.
73. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A. Fattaey A and McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376, 1996.
74. Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza F, Morgan DO, Barnes G, LeClerc S, Meijer L, Kim SH, Lockhart DJ and Schultz PG: Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281: 533-538, 1998.